The prognostic significance of the alterations of pulmonary hemodynamics in patients with pulmonary arterial hypertension: a meta-regression analysis of randomized controlled trials

Shih-Hsien Sung1,2, Wan-Yu Yeh3, Chern-En Chiang2,4, Chi-Jung Huang3, Wei-Ming Huang1,2, Chen-Huan Chen2,5,6 and Hao-Min Cheng2,3,5,6*

Abstract

Background: Hemodynamic assessment in patients with pulmonary arterial hypertension (PAH) is essential for risk stratification and pharmacological management. However, the prognostic value of the hemodynamic changes after treatment is less well established.

Objectives: We investigated the prognostic impacts of the changes in hemodynamic indices, including mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), right atrial pressure (RAP), and cardiac output index (CI). We conducted this systematic review with meta-regression analysis on existing clinical trials.

Methods: We searched and identified all relevant randomized controlled trials from multiple databases. An analogous R² index was used to quantify the proportion of variance explained by each predictor in the association with PAH patients’ prognosis. A total of 21 trials and 3306 individuals were enrolled.

Results: The changes in mPAP, PVR, RAP, and CI were all significantly associated with the change in 6MWD (Δ6MWD). The change in mPAP was associated with the highest explanatory power for Δ6MWD (R² analog = 0.740). Additionally, the changes in mPAP, PVR, and CI were independently predictive of adverse clinical events. The change in mPAP had the highest explanatory power for the clinical events (R² analog = 0.911). Furthermore, the change in PVR was associated with the highest explanatory power for total mortality of PAH patients (R² analog = 0.612).

Conclusion: Hemodynamic changes after treatment, including mPAP, PVR, CI, and RAP, were significantly associated with adverse clinical events or mortality in treated PAH patients. It is recommended that further studies be conducted to evaluate the changes in hemodynamic indices to guide drug titration.

Systematic review registration: PROSPERO CRD42019125157

Keywords: Pulmonary arterial hypertension, Hemodynamics, Meta-regression, Meta-analysis

Introduction

Although there have been significant advances in pharmacological therapies in the past decade, pulmonary arterial hypertension (PAH) remains a progressive and fatal disease. The 2015 ESC/ERS Pulmonary Hypertension...
guidelines have strongly recommended comprehensive screening protocols for high-risk populations and subsequent early intervention [1]. In addition, upfront combination therapy and aggressive medical escalations were also suggested in the treatment of PAH patients. Given the variable long-term survival rates between patients, risk stratification has been endorsed in the clinical management of PAH. While the European guideline has proposed a risk prediction algorithm, comprising 9 measures [1], Benza et al. also computed a risk score calculator for 1-year survival in 504 individuals from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) [2]. However, the routine clinical application was limited due to the complexity of these predictive algorithms. Hooper et al., therefore, validated a simplified risk stratification strategy for mortality, including World Health Organization functional class (WHO FC), 6-min walking distance (6WMD), brain natriuretic peptide or its N-terminal fragment, right atrial pressure (RAP), and cardiac index (CI) in a cohort of 1588 PAH patients [3]. Despite the existing prediction models, the prognostic significance of the changes of these parameters during treatment for patients with PAH has not been systematically examined.

The pathophysiology of PAH is characterized by increased pulmonary vascular resistance (PVR) at the beginning, followed by elevated pulmonary arterial pressure (PAP), decreased cardiac output, and increased RAP. The published data have supported that the hemodynamic indices, including PVR, cardiac output, and RAP were predictive of clinical outcomes among PAH patients [4, 5]. However, it remains debated whether the changes in the hemodynamic parameters are predictive of clinical outcomes. Although the non-invasive variables have been widely recommended to assess the risks in PAH, the mismatch between pulmonary resistance and RV contractility remains the main cause of mortality. We, therefore, conducted a systemic review to investigate the prognostic values of the changes in hemodynamic indices in PAH.

Methods
The protocol for this review has been registered in PROSPERO (registration number CRD42019125157), and the study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines version 2020 (Supplementary Table 1) [6].

Search strategy
All relevant studies from EMBASE, MEDLINE, Cochrane Library, and PubMed through August 2021, were searched and identified using the following keywords and the Medical Subject Headings (MeSH) terms: Pulmonary hypertension, Pulmonary Arterial Hypertension, PH, and PAH. No language restrictions were applied on any of these searches. We limited our searches to randomized controlled trials (RCTs) that compare either the effects of any of the 9 drug classes (ERA, PDE5, PDGFR, Prostacyclin, Prostacyclin plus ERA, Rho-kinase, TXSI/TXRA, sGC) with placebo or the effects between 2 drug classes. In the process of formulating the search strategy, the research team not only revised and discussed the preliminary search results to find a consensus but also consulted the librarians of the research institution to refer to their suggestions. Given the study is the secondary analysis of the published data, the review was waived by the ethical committee of Taipei Veterans General Hospital.

Inclusion and exclusion criteria
Studies were eligible only if they reported any or all of the following outcomes: hospitalization for PAH, death due to PAH, total mortality, all adverse events of hospitalization and all-cause death, and exercise capacity (as measured by a 6-min walk distance, 6MWD). Additional studies were retrieved by manually checking the reference lists of reviews, meta-analyses, and original publications. Finally, we excluded RCT studies investigating pediatric PAH (age < 12) and those that did not report sequential measurements of cardiopulmonary hemodynamics, including mPAP, PVR, RAP, CI, or pulmonary artery wedge pressure (PAWP). For studies with more than one publication, only the studies with the largest number of participants in the trial were retained. The search of eligible studies was done separately by 2 investigators (W. Y. Yeh and W.M. Huang). The consensus was then reached through discussion and the arbitration of the principal investigator (H.M. Cheng). Of 603 articles identified by the initial search, 39 were retrieved for more detailed evaluation, and 21 trials were included in the study. The selection process of the literature search is shown in Fig. 1. The International prospective register of systematic reviews (PROSPERO) registration number of this study is CRD42019125157 (URL: https://www.crd.york.ac.uk/PROSPERO/).

Data extraction
To calculate the unit consistency, the standard deviations were all converted to standard error (divided by the square root of the sample number), 95% confidence intervals were converted to standard errors (= [upper limit-lower limit]/3.92). If the actual data is not presented in the study and only graphically, we use WebPlotDigitizer version 4.1 [7] to interpolate the approximate data. In addition, for studies reporting PVR in Woods units, we multiplied this value by 80 to obtain the PVR in dyne-sec/cm².
Data were extracted from papers by 2 investigators (W. Y. Yeh and C. J. Huang) independently, and differences in data extraction were resolved through discussions with the third investigator (H.M. Cheng).

**Data synthesis and statistical analysis**

Weighted meta-regression analysis was performed to examine the relationship between hemodynamics changes before/after the interventions and outcome variables included in this study by Comprehensive Meta-Analysis version 3.3.070 [8]. For this analysis, the achieved differences between the changes in 6MWD (Δ6MWD), and the event numbers of hospitalization and deaths in active treatment and control groups were considered.

For the assessment of the regression coefficient of each hemodynamic parameter with Δ6MWD and clinical outcomes, and changes in mPAP (ΔmPAP), PVR (ΔPVR), RAP (ΔRAP), and CI (ΔCI), were entered into the meta-regression model separately with the adjustment of age, sex, and baseline WHO function class. The prognostic values of ΔmPAP, ΔPVR, ΔRAP, ΔCI, and Δ6MWD were evaluated by using the univariate meta-regression model. For all meta-regression analyses, a random-effects model was used, and the analogous $R^2$ analog was adopted to quantify the proportion of variance explained by the entered covariate(s) in meta-regression. Tau$^2$ and the restricted maximum likelihood (REML) methods were used to explain residual heterogeneity not explained by the covariate(s) [8, 9]. If there were missing values of the
hemodynamic parameters or outcomes in the enrolled studies, the missing data were excluded from the meta-regression analysis.

Assessment of risk of bias and level of evidence
The quality of studies was assessed by using the Cochrane Risk of Bias tool to assess the quality of these randomized controlled trials. The following 7 main domains are used in the assessment: (1) bias arising from the randomization; (2) bias due to inappropriate allocation process; (3) bias due to blinding of participants or outcome data assessment; (4) bias due to missing outcome data; (5) bias in measurement of the outcome; (6) bias in selection of the reported result; (7) other bias that may significantly affect the interpretation of the results. Bias is assessed as a judgment of high, low, or unclear. Trials with high or unclear risk for bias were considered with a high risk of bias. The quality of overall evidence and strength of recommendation for Δ6MWD (Y1), all adverse events (Y2), total mortality (Y3), hospitalization for PAH (Y4), and death due to PAH (Y5) were further determined (refer to the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach with the use of GRADEpro software (https://gradepro.org/)) [10], including the dimensions of Indirectness, Imprecision, Publication bias, and the Certainty/Importance of the overall evidence, while the indicator of effect is modified to the adjusted regression coefficient of meta-regression (Supplemental Table S1).

Each item of the Cochrane Risk of Bias tool and Grade tool were also independently assessed by 2 investigators (S. H. Sung and W. Y. Yeh), and the disparities during this assessment process were determined by the principal investigator (H.M. Cheng).

Results
Characteristics of the included studies
A total of 21 RCTs and 3306 PAH patients, published between 1996 and 2013 were recruited in this analysis [11–31]. Supplemental Table S2 has shown the characteristics of each RCT, and the mean age of the study population ranged from 29 to 56 years. Of all the participants, 1097 received a placebo, and 2166 were treated with active drugs. The changes in hemodynamic indices, including ∆mPAP, ∆PVR, ∆RAP, and ∆CI, correlated with the Δ6MWD, after accounting for age, sex, and baseline functional class (Table 1, Fig. 2). Patients with increasing mPAP, PVR, and RAP were independently associated with less improvement of 6MWD ($\beta = -7.1067, -0.1046, \text{and} -10.6923$, respectively), and increasing change in CI was independently related to better improvement of 6MWD ($\beta = 42.4492$). Concerning the clinical outcomes, after accounting for age, sex, and baseline functional class, increased ΔmPAP and ΔPVR, and decreased ΔCI were associated with more adverse clinical events ($\beta = 0.1794, 0.0031, \text{and} -1.7544$, respectively) (Table 1, Fig. 2). While ΔmPAP was the variable with the highest explanatory power for Δ6MWD ($R^2$ analog = 0.74), it also had the highest explanatory power for the incident adverse events ($R^2$ analog = 0.91) among the 4 hemodynamic indices. On the other hand, increased ΔPVR and decreased ΔCI were related to higher mortality rates ($\beta = 0.0022 \text{and} -1.2136$, respectively). In addition, none of the changes in hemodynamic indices was significantly related to the hospitalizations for PAH or death due to PAH in multivariate meta-regression analysis. Moreover, Δ6MWD did not correlate with any adverse event, neither.

Risks of bias among the included studies
The risk of bias among the 21 RCTs was evaluated in 7 categories (Supplemental Figure S1), and researchers presented higher or uncertain risk aspects including (1) allocation concealment: 18 articles had no detailed description; (2) blinding of outcome assessment: 15 articles had no clear description, but the 6MWD, hospitalizations, and mortality were objectively evaluated indicators, which were less susceptible to human subjective assessment; (3) selective reporting: 13 articles unlisted study protocol to check the reported and unreported findings, nor a special statement about the containment of all expected outcomes; therefore, there is a lack of sufficient information to determine whether it is possible to selectively report some study results. Because the main purpose of this study was to investigate the prognostic values of the changes in pulmonary hemodynamics, the study results should be less susceptible to the aforementioned risk of bias. Therefore, the 21 studies were all included in the subsequent meta-regression analysis.

GRADE assessment
In addition, the assessment of the quality of the body of evidence was shown in Supplemental Table S4. In the GRADE Evidence Profile, the level of evidence for Δ6MWD was downgraded because of Indirectness concern (surrogate endpoint). Hospitalization for PAH was also downgraded because of Imprecision concerns (few incidents) ($n = 4$). Considering the overall quality of the
Discussion

In this meta-regression analysis of 21 RCTs and 3306 participants, we demonstrated all the changes in hemodynamic indices, including ΔmPAP, ΔPVR, ΔRAP, and ΔCI, were associated with Δ6MWD, independent of age, sex, and baseline functional class. However, only ΔmPAP, ΔPVR, and ΔCI, but not ΔRAP or Δ6MWD were related to clinical adverse events, after accounting for age, sex, and functional class. In addition, only ΔPVR and ΔCI were the hemodynamic parameters to be independently predictive of total mortality. But none of the changes in hemodynamic indices was correlated with PAH hospitalization or death due to PAH. The study results may support the use of the changes in the hemodynamic parameters, including ΔmPAP, for the risk assessment in the management of PAH.

Hemodynamic indices and the prognosis

Although elevated mPAP is essential in the diagnosis of PAH and small increases in mPAP are independently associated with increased mortality in patients with borderline pulmonary hypertension [32, 33], several studies did not demonstrate any association between mPAP and the survival in PAH patients [4, 5]. Benza et al. have shown RAP but not mPAP was associated with 1-year survival in the REVEAL registry of 2716 subjects [34]. In contrast, CI among the hemodynamic indices was suggested to be predictive of clinical outcomes in European cohorts of PAH [3, 35]. Since the difference between mPAP and PAWP is the product of cardiac output multiplied by PVR, the increase in PVR and the decrease in cardiac output along with the progression of PAH could partially cancel their effects on mPAP. Conversely, an increase in mPAP could result from an augment in cardiac output due to improving PAH and might not be due to a rise in PVR from deteriorating PAH. Therefore, the

\[
\begin{array}{|c|c|c|c|}
\hline
\text{Outcomes} & \text{Predictors} & \text{Coefficient}^a & \text{P value}^b & \text{R}^2\text{ analoga} \\
\hline
(\text{Y1}) \Delta6MWD & (X1) \Delta \text{mPAP} & -7.1067 & <.0001 & .7397 \\
 & (X2) \Delta \text{PVR} & -0.1046 & <.0001 & .6442 \\
 & (X3) \Delta \text{RAP} & -10.6923 & .0093 & .1011 \\
 & (X4) \Delta \text{CI} & 42.4492 & <.0001 & .4574 \\
\hline
(\text{Y2}) \text{All adverse events} & (X1) \Delta \text{mPAP} & 0.1794 & .0048 & .9111 \\
 & (X2) \Delta \text{PVR} & 0.0031 & .0015 & .8217 \\
 & (X3) \Delta \text{RAP} & 0.2191 & .1109 & .5224 \\
 & (X4) \Delta \text{CI} & -1.7544 & .0004 & .7701 \\
 & (X5) \Delta6MWD & -0.0141 & .1195 & .6511 \\
\hline
(\text{Y3}) \text{Total mortality} & (X1) \Delta \text{mPAP} & 0.1143 & .0932 & 5.498 \\
 & (X2) \Delta \text{PVR} & 0.0022 & .0332 & .6116 \\
 & (X3) \Delta \text{RAP} & 0.2412 & .0796 & .5567 \\
 & (X4) \Delta \text{CI} & -1.2136 & .0250 & .6055 \\
 & (X5) \Delta6MWD & -0.0080 & .2600 & .7046 \\
\hline
(\text{Y4}) \text{Hospitalization for PAH} & (X1) \Delta \text{mPAP} & 0.1420 & .0519 & 2.792 \\
 & (X2) \Delta \text{PVR} & 0.0024 & .1174 & .5761 \\
 & (X3) \Delta \text{RAP} & 0.0733 & .6571 & .0000 \\
 & (X4) \Delta \text{CI} & -0.6668 & .3520 & .0000 \\
 & (X5) \Delta6MWD & -0.0079 & .2847 & .0704 \\
\hline
(\text{Y5}) \text{Death due to PAH} & (X1) \text{mPAP} & 0.0548 & .6496 & .0000 \\
 & (X2) \Delta \text{PVR} & 0.0020 & .4046 & .0000 \\
 & (X3) \Delta \text{RAP} & -0.0016 & .9552 & .0000 \\
 & (X4) \Delta \text{CI} & -0.7086 & .5299 & .0000 \\
 & (X5) \Delta6MWD & 0.0005 & .9688 & .0000 \\
\hline
\end{array}
\]

\(^a\) Adjusted for age, sex, and baseline WHO function class

\(^b\) Results of univariate regression analysis
determinants of mPAP could vary on different stages of right ventricular failure, and the prognostic value of mPAP in PAH patients is expected to be low. However, D’Alonzo et al. showed that a higher mPAP at the diagnosis of PAH conferred a greater risk of early death in a cohort of 194 patients [36]. Moreover, Sitbon et al. identified an paradoxical correlation between low baseline mPAP and mortality in 178 patients with PAH in WHO functional class III or IV [37]. In patients with severe PAH and right ventricular failure, low mPAP may better correlate with low cardiac output rather than low PVR, indicating worse outcomes [37]. On the other hand, few studies have investigated the association between the changes in hemodynamic indices and outcomes in patients with PAH. Weatherald et al. presented a PAH cohort of 981 patients who had undergone repeated hemodynamic surveys in a mean time of 4.6 months [38]. The results suggested that ΔmPAP and ΔPVR were significantly associated with death or lung transplantation in the whole study population, while ΔCI was only predictive of clinical outcomes in the subgroup of severe PAH patients [38].

In the present study, we have shown that ΔmPAP, ΔPVR, ΔRAP, and ΔCI were all crudely correlated with clinical adverse events. After accounting for age, sex, and WHO functional class, ΔmPAP, ΔPVR, and ΔCI remained significantly related to clinical outcomes. The study results may support the inclusion of these indices in the simplified risk score for the prediction of disease outcomes [35].

The 6-min walk distance
The change from baseline in 6MWD (Δ6MWD) has long-term served as the surrogate endpoint in the clinical trials of PAH to evaluate the therapeutic efficacy of the study drugs. It is expected that the indirect measure of 6MWD may reflect the clinically meaningful endpoints, such as quality of life and survival. The SERAPHIN study may have firstly endorsed the directly clinical outcomes as the primary endpoint to demonstrate that macitentan significantly reduced morbidity and mortality among patients with PAH [39]. However, the Δ6MWD was not associated with the long-term outcomes [40]. In a meta-analysis of 16 short-term RCTs, Macchia et al. have
shown the Δ6MWD was not predictive of a survival benefit or adverse clinical events [41]. The updated meta-analyses have demonstrated again that the Δ6MWD did not correlate with any of the composite clinical events, including mortality, hospitalization for PAH, lung transplantation, or the initiation of rescue therapy [42, 43]. The present study also found that Δ6MWD was not associated with clinical outcomes. The results support the use of morbidity and mortality rather than Δ6MWD as the primary endpoint in the RCTs for PAH patients.

Limitations
The long-term prognostic values of hemodynamic changes have not been evaluated in large cohorts yet. Although meta-regression analysis may improve our understandings of the associations between hemodynamic indices and the long-term clinical outcomes, the variances of baseline characteristics, study designs, and background therapies across the enrolled RCTs can cause biased study findings. Some RCTs were undertaken to prove the short-term effects of a novel drug mainly on exercise capacity. Although the others might have been designed to evaluate the therapeutic effects on long-term mortality and morbidities, caution should be exercised to interpret the correlations between hemodynamic changes and clinical outcomes. For patients with early PAH and preserved right ventricular function, the therapeutic changes in CI might be subtle, and the changes in mPAP may reflect the changes in PVR. In patients with PAH and profound right ventricular failure, improvement of CI followed by increased mPAP may indicate significant amelioration of right ventricular dysfunction, and better long-term outcomes were expected. While connective tissue disease is the second common etiologies of PAH, it may cause direct damage on the myocardium rather than through PAH. The inclusion of these subjects with distinct pathophysiology in the previously published RCTs may influence the findings observed in the present meta-regression analysis. In addition, lung transplantation was not statistically reported as an isolated endpoint in the majority of the studies. Although lung transplantation was even identical to the mortality event, the study was not able to analyze the associated impacts due to insufficient data. Moreover, the study results are based on published RCTs, in some of which currently available PAH drugs were not commercially available.

Future directions
Given that the pulmonary hemodynamics are essentially related to long-term survival, the non-invasive assessments of the risk features are currently encouraged for the management of PAH to improve the guideline implementation [35]. While the cross-sectional hemodynamic evaluations have been predictive of clinical events, the measures of the changes in hemodynamics may further disclose the prognostic information in response to PAH therapy. However, future studies are needed to evaluate the effectiveness of hemodynamic-guided treatment, stratified by PAH etiologies and right ventricular function.

Conclusions
Progression of PAH is usually characterized by increasing mPAP, PVR, and RAP, and decreasing CI, and this study aggregates the evidence of existing RCTs for verification. In addition to the baseline and on-treatment hemodynamic measures, the present study demonstrates that ΔmPAP, ΔPVR, ΔRAP, and ΔCI were all significantly associated with the surrogate endpoint (Δ6MWD). Furthermore, ΔPVR and ΔCI were significantly associated with mortality, and ΔmPAP, ΔPVR, and ΔCI correlated with adverse clinical events of PAH patients. Given that risk stratification is essential in the management of PAH, further studies are warranted to evaluate whether the changes in the hemodynamic indices could be used to evaluate the therapeutic effects, in addition to the clinical risk factors, including functional class, 6MWD, and NT-proBNP.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13643-021-01816-0.

Abbreviations
PAH: Pulmonary arterial hypertension; mPAP: Pulmonary artery pressure; PVR: Pulmonary vascular resistance; RAP: Right atrial pressure; CI: Cardiac output index; 6WMD: 6-min walking distance; MeSH: Medical Subject Headings.

Authors’ contributions
All authors have drafted the work or revised it critically for important intellectual content; given final approval of the version to be published, and provided agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The individual contributions of each author are detailed below: Shih-Hsien Sung: Conception or design of the work; the acquisition, analysis, and interpretation of data for the work. Wan-Yu Yeh: Analysis, and interpretation of data for the work. Chi-Jung Huang: Analysis, and interpretation of data for the work. Wei-Ming Huang: Acquisition and interpretation of data for the work. Hao-Min Cheng: Conception or design of the work; the acquisition, analysis, and interpretation of data for the work.
Funding
This study was supported by Grants from the Ministry of Health and Welfare (MOHW104-TDU-B-211-113-003, MOHW106-TDU-B-211-113001, MOHW110-TDU-B-211-124001).

Availability of data and materials
The database of the present study can be made available on reasonable request to the corresponding author.

Declarations

Ethics approval and consent to participate
The present study is the secondary analysis of the published data without any human primary data. It has been waived for the review by our ethical committee (Taipei Veterans General Hospital) according to the regulation of our hospital.

Consent for publication
Not applicable (Our manuscript does not contain data from any individual person).

Competing interests
The authors declare that they have no competing interests.

Author details
1. Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 2. Department of Medicine, National Yang Ming Chiao Tung University, School of Medicine, Taipei, Taiwan. 3. Center for Evidence-based Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Beitou District, Taipei, Taiwan. 4. General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan. 5. Institute of Public Health and Community Medicine Research Center, National Yang Ming Chiao Tung University, School of Medicine, Taipei, Taiwan. 6. Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.

Received: 19 April 2021 Accepted: 15 September 2021
Published online: 30 October 2021

References

1. Galie N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/EERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPCC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.

2. Benza RL, Miller DF, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012;142(2):448–56.

3. Hoeper MM, Kramer T, Pan Z, Eichtaedt CA, Spiesshoeffer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2):1700740.

4. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, et al. Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation. 1994;89(4):1733–44.

5. Kawut SM, Horn EM, Berekashvili KK, Garofano RP, Goldsmith RL, Wdowicz AC, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol. 2005;95(2):199–203.

6. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2015 statement: an updated guideline for reporting systematic reviews. BMJ. 2015;352:z711.

7. Rohatgi A. Webplotdigitizer 4.1-extract data from plots, images, and maps, 2018.

8. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. Chichester: Wiley; 2011.

9. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18(20):2693–708.

10. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. Grade guidelines: 1. Introduction—grade evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.

11. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;335(4):296–301.

12. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled trial. Lancet. 2001;358(9288):1119–23.

13. Galie N, Humbert M, Vachiery J-L, Vizza C, Knueissl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Am J Cardiol. 2002;90(9):1496–502.

14. Olchewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–9.

15. Langleben D, Christman BW, Barst RJ, Dias VC, Galie N, Higenbottam TW, et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist trebogrel in patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 2002;165(6):800–4.

16. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–4.

17. Barst RJ, McGoon M, McLaughlin V, Tapson V, Oudiz R, Shapiro S, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(2):2119–25.

18. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169(4):441–7.

19. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Silde nanil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2003;353(20):2148–57.

20. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. Sildenafil versus endethelin receptor antagonist for pulmonary hypertension (seraph) study. Am J Respir Crit Care Med. 2005;171(11):1292–7.

21. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(4):48–54.

22. McLaughlin VW, Oudiz RJ, Frost A, Tapson VF, Muriali S, Channick RN, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257–63.

23. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34(12):2417–22.

24. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521–30.

25. Galie N, Rubin L, Hoeper M, Jansa P, Ah-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (early study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093–100.

26. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Randomised study of adding inhaled iloprost to existing bosentan in patients with pulmonary arterial hypertension: a randomised placebo-controlled study. Eur Respir J. 2011;37(2):2894–903.

27. Jing Z-C, Yu Z-X, Shen J-Y, Wu B-X, Xu K-F, Zhu X-Y, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183(2):1723–9.

28. Zeng W-J, Xiong C-M, Zhao L, Shan G-L, Liu Z-H, Xue F, et al. Atorvastatin in pulmonary hypertension (APATHS) study. Eur Respir J. 2012;40(1):67–74.

29. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M,UCHino K, Yoo A, et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013;77(10):2619–25.
30. Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.
31. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocaı K, Galie N, et al. Selexipag: an oral, selective prostacyclin receptor-agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874–80.
32. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation. 2016;133(13):1240–8.
33. Assad TR, Maron BA, Robbins IM, Xu M, Huang S, Harrell FE, et al. prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension. JAMA Cardiol. 2017;2(12):1361–8.
34. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (reveal). Circulation. 2010;122(2):164–72.
35. Bouchl A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889.
36. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Blundage BH, Dettre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115(5):343–9.
37. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.